A Focus on High Dose Omega-3 Fatty… (2024)

1. Heron M. Deaths: leading causes for 2012. National Vital Statistics Reports. 2015;64.
2. Murphy SA, Cannon CP, Wiviott SD, McCabe CH, Braunwald E. Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) trial. J Am Coll Cardiol. 2009;54:2358–62.
   https://doi.org/10.1016/j.jacc.2009.10.005
3. Tikkanen MJ, Szarek M, Fayyad R, et al. Total cardiovascular disease burden: comparing intensive with moderate statin therapy insights from the IDEAL (incremental decrease in end points through aggressive lipid lowering) trial. J Am Coll Cardiol. 2009;54:2353–7.
   https://doi.org/10.1016/j.jacc.2009.08.035
4. Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670–81.
   https://doi.org/10.1016/S0140-6736(10)61350-5
5. Jacobson TA, Ito MK, Maki KC, et al. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1—full report. J Clin Lipidol. 2015;9:129–69.
   https://doi.org/10.1016/j.jacl.2015.02.003
6. Jacobson TA, Maki KC, Orringer CE, et al. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 2. J Clin Lipidol. 2015;9:S1–122.
   https://doi.org/10.1016/j.jacl.2015.09.002
7. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63:2889–934.
   https://doi.org/10.1016/j.jacc.2013.11.002
8. Miller M, Cannon CP, Murphy SA, Qin J, Ray KK, Braunwald E. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol. 2008;51:724–30.
   https://doi.org/10.1016/j.jacc.2007.10.038
9. Faergeman O, Holme I, Fayyad R, et al. Plasma triglycerides and cardiovascular events in the treating to new targets and incremental decrease in end-points through aggressive lipid lowering trials of statins in patients with coronary artery disease. Am J Cardiol. 2009;104:459–63.
   https://doi.org/10.1016/j.amjcard.2009.04.008
10. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372:2387–97.
    https://doi.org/10.1056/NEJMoa1410489
11. Miller M, Stone NJ, Ballantyne C, et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2011;123:2292–333.
    https://doi.org/10.1161/CIR.0b013e3182160726
12. Berglund L, Brunzell JD, Goldberg AC, et al. Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2012;97:2969–89.
    https://doi.org/10.1210/jc.2011-3213
13. Catapano AL, Reiner Z, DeBacker G, et al. The Task Force for the management of dyslipidemia of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis. 2011;217:S1–44.
    https://doi.org/10.1016/j.atherosclerosis.2011.06.028
14. Catapano AL, Graham I, DeBacker G, et al. 2016 ESC/EAS guidelines for the management of dyslipidemias. The task force for the management of dyslipidemia of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Atherosclerosis. 2016;253:281–344.
    https://doi.org/10.1016/j.atherosclerosis.2016.08.018
15. National Lipid Association Triglyceride Awareness Survey results. Available from: https://www.lipid.org/search/node/Hypertriglyceridemia%20Awareness%20Survey%20Results . Accessed August 11, 1016.
16. Food and Drug Administration. Withdrawal of approval of indications related to the coadministration with statins in applications for niacin extended-release tablets and fenofibric acid delayed-release capsules. Available from: https://s3.amazonaws.com/public-inspection.federalregister.gov/2016-08894.pdf . Accessed April 29, 2016.
17. Cohen JD, Cziraky MJ, Cai Q, et al. 30-year trends in serum lipids among United States adults: results from the national health and nutrition examination surveys II, III, and 1999-2006. Am J Cardiol. 2010;106:969–75.
    https://doi.org/10.1016/j.amjcard.2010.05.030
18. Flegal KM, Kruszon-Moran D, Carroll MD, Fryar CD, Ogden CL. Trends in obesity among adults in the United States, 2005 to 2014. JAMA. 2016;315:2284–91.
    https://doi.org/10.1001/jama.2016.6458
19. Christian JB, Bourgeois N, Snipes R, Lowe KA. Prevalence of severe (500 to 2000 mg/dL) hypertriglyceridemia in United States adults. Am J Cardiol. 2011;107:891–7.
    https://doi.org/10.1016/j.amjcard.2010.11.008
20. Carroll M, Kit B, Lacher D. Trends in elevated triglyceride in adults: United States, 2001–2012. NCHS Data Brief. 2015:1–8.
21. Sumner AE, Finley KB, Genovese DJ, Criqui MH, Boston RC. Fasting triglyceride and the triglyceride-HDL cholesterol ratio are not markers of insulin resistance in African Americans. Arch Intern Med. 2005;165:1395–400.
    https://doi.org/10.1001/archinte.165.12.1395
22. Chhabra S, Narang R, Krishnan LR, et al. Apolipoprotein C3 SstI polymorphism and triglyceride levels in Asian Indians. BMC Genet. 2002;3:9.
    https://doi.org/10.1186/1471-2156-3-9
23. Resnick HE, Foster GL, Bardsley J, Ratner RE. Achievement of American Diabetes Association clinical practice recommendations among U.S. adults with diabetes, 1999–2002: the National Health and Nutrition Examination Survey. Diabetes Care. 2006;29:531–7.
    https://doi.org/10.2337/diacare.29.03.06.dc05-1254
24. Weiner DE, Sarnak MJ. Managing dyslipidemia in chronic kidney disease. J Gen Intern Med. 2004;19:1045–52.
    https://doi.org/10.1111/j.1525-1497.2004.40049.x
25. Tenner S, Baillie J, DeWitt J, Vege SS. American College of Gastroenterology guideline: management of acute pancreatitis. Am J Gastroenterol. 2013;108:1400–15.
    https://doi.org/10.1038/ajg.2013.218
26. Scherer J, Singh VP, Pitchumoni CS, Yadav D. Issues in hypertriglyceridemic pancreatitis: an update. J Clin Gastroenterol. 2014;48:195–203.
    https://doi.org/10.1097/01.mcg.0000436438.60145.5a
27. Murphy MJ, Sheng X, MacDonald TM, Wei L. Hypertriglyceridemia and acute pancreatitis. JAMA Intern Med. 2013;173:162–4.
    https://doi.org/10.1001/2013.jamainternmed.477
28. Linares CL, Pelletier AL, Czernichow S, et al. Acute pancreatitis in a cohort of 129 patients referred for severe hypertriglyceridemia. Pancreas. 2008;37:13–8.
    https://doi.org/10.1097/MPA.0b013e31816074a1
29. Ewald N, Hardt PD, Kloer HU. Severe hypertriglyceridemia and pancreatitis: presentation and management. Curr Opin Lipidol. 2009;20:497–504.
    https://doi.org/10.1097/MOL.0b013e3283319a1d
30. Yang F, Wang Y, Sternfeld L, et al. The role of free fatty acids, pancreatic lipase and Ca+ signalling in injury of isolated acinar cells and pancreatitis model in lipoprotein lipase-deficient mice. Acta Physiol (Oxf.). 2009;195:13–28.
31. Yadav D, Pitchumoni CS. Issues in hyperlipidemic pancreatitis. J Clin Gastroenterol. 2003;36:54–62.
    https://doi.org/10.1097/00004836-200301000-00016
32. Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA. 2007;298:299–308.
    https://doi.org/10.1001/jama.298.3.299
33. Freiberg JJ, Tybjaerg-Hansen A, Jensen JS, Nordestgaard BG. Nonfasting triglycerides and risk of ischemic stroke in the general population. JAMA. 2008;300:2142–52.
    https://doi.org/10.1001/jama.2008.621
34. Di Angelantonio E, Sarwar N, Perry P, et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009;302:1993–2000.
    https://doi.org/10.1001/jama.2009.1619
35. Sarwar N, Danesh J, Eiriksdottir G, et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation. 2007;115:450–8.
    https://doi.org/10.1161/CIRCULATIONAHA.106.637793
36. Nordestgaard BG, Varbo A. Triglycerides and cardiovascular disease. Lancet. 2014;384:626–35.
    https://doi.org/10.1016/S0140-6736(14)61177-6
37. Chapman MJ, Ginsberg HN, Amarenco P, et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J. 2011;32:1345–61.
    https://doi.org/10.1093/eurheartj/ehr112
38. Schwartz GG, Abt M, Bao W, et al. Fasting triglycerides predict recurrent ischemic events in patients with acute coronary syndrome treated with statins. J Am Coll Cardiol. 2015;65:2267–75.
    https://doi.org/10.1016/j.jacc.2015.03.544
39. Sarwar N, Sandhu MS, Ricketts SL, et al. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet. 2010;375:1634–9.
    https://doi.org/10.1016/S0140-6736(10)60545-4
40. Varbo A, Benn M, Tybjaerg-Hansen A, Jorgensen AB, Frikke-Schmidt R, Nordestgaard BG. Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol. 2013;61:427–36.
    https://doi.org/10.1016/j.jacc.2012.08.1026
41. The TG, HDL Working Group of the Exome Sequencing Project, National Heart, Lung, and Blood Institute, Crosby J, Peloso GM, et al. Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med. 2014;371:22–31.
    https://doi.org/10.1056/NEJMoa1307095
42. Jorgensen AB, Frikke-Schmidt R, Nordestgaard BG, Tybjaerg-Hansen A. Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. N Engl J Med. 2014;371:32–41.
    https://doi.org/10.1056/NEJMoa1308027
43. Brunzell JD, Hazzard WR, Porte D Jr, Bierman EL. Evidence for a common saturable triglyceride removal mechanism for chylomicrons and very low density lipoprotein in man. J Clin Invest. 1973;52:1578–85.
    https://doi.org/10.1172/JCI107334
44. Christian JB, Arondekar B, Boysman EK, et al. Determining triglyceride reductions needed for clinical impact in sever hypertriglyceridemia. Am J Med. 2014;127:36–44.
    https://doi.org/10.1016/j.amjmed.2013.09.018
45. Blaha MJ, Blumenthal RS, Brinton EA, Jacobson TA. National Lipid Association Taskforce on Non-HDL Cholesterol. The importance of non-HDL cholesterol in reporting in lipid management. J Clin Lipidol. 2008;2:267–73.
    https://doi.org/10.1016/j.jacl.2008.06.013
46. Mora S, Buring J, Ridker PM. Discordance of low-density lipoprotein (LDL) cholesterol with alternative LDL-related measures and future coronary events. Circulation. 2014;129:553–61.
    https://doi.org/10.1161/CIRCULATIONAHA.113.005873
47. Ballantyne CM, Olsson AG, Cook TJ, Mercuri MF, Pedersen TR, Kjekshus J. Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation. 2001;104:3046–51.
    https://doi.org/10.1161/hc5001.100624
48. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987;317:1237–45.
    https://doi.org/10.1056/NEJM198711123172001
49. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 1999;341:410–8.
    https://doi.org/10.1056/NEJM199908053410604
50. Manninen V, Tenkanen L, Koskinen P, et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation. 1992;85:37–45.
    https://doi.org/10.1161/01.CIR.85.1.37
51. Robins SJ, Collins D, Wittes JT, et al. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA. 2001;285:1585–91.
    https://doi.org/10.1001/jama.285.12.1585
52. Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366:1849–61.
    https://doi.org/10.1016/S0140-6736(05)67667-2
53. ACCORD Study Group, Ginsberg HN, Elam MB, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362:1563–74.
    https://doi.org/10.1056/NEJMoa1001282
54. Scott R, O’Brien R, Fulcher G, et al. Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care. 2009;32:493–8.
    https://doi.org/10.2337/dc08-1543
55. Boden WE, Probstfield JL, Anderson T, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365:2255–67.
    https://doi.org/10.1056/NEJMoa1107579
56. Landray MJ, Haynes R, Hopewell JC, et al. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014;371:203–12.
    https://doi.org/10.1056/NEJMoa1300955
57. Guyton JR, Slee AE, Anderson T, et al. Relationship of lipoproteins to cardiovascular events: the AIM-HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides and Impact on Global Health Outcomes). J Am Coll Cardiol. 2013;62:1580–4.
    https://doi.org/10.1016/j.jacc.2013.07.023
58. Yokoyama M, Origasa H, Matsuzaki M, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet. 2007;369:1090–8.
    https://doi.org/10.1016/S0140-6736(07)60527-3
59. Saito Y, Yokoyama M, Origasa H, et al. Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS). Atherosclerosis. 2008;200:135–40.
    https://doi.org/10.1016/j.atherosclerosis.2008.06.003
60. Clinicaltrials.gov. A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High Risk Patients With Hypertriglyceridemia and on Statin. The Primary Objective is to Evaluate the Effect of 4 g/Day AMR101 for Preventing the Occurrence of a First Major Cardiovascular Event. (REDUCE-IT). Available from: https://clinicaltrials.gov/ct2/show/NCT01492361 . Accessed April 29, 2016.
61. Clinicaltrials.gov. Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia (STRENGTH). Available from: https://clinicaltrials.gov/ct2/show/NCT02104817 . Accessed April 29, 2016.
62. Zargar A, Ito MK. Long chain omega-3 dietary supplements: a review of the National Library of Medicine Herbal Supplement Database. Metab Syndrom Related Dis. 2011;9:255–71.
    https://doi.org/10.1089/met.2011.0004
63. Amarin Corporation. Vascepa prescibing information. Available from: http://www.vascepa.com/full-prescribing-information.pdf . Accessed April 29, 2016.
64. GlaxoSmithKline. Lovaza prescribing information. Available from: https://www.gsksource.com/gskprm/htdocs/documents/LOVAZA-PI-PIL.PDF . Accessed April 29, 2016.
65. Trygg Pharma. Omtryg prescribing information. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204977s000lbl.pdf . Accessed April 29, 2016.
66. AstraZeneca. Epanova prescribing information. Available from: http://www1.astrazeneca-us.com/pi/epanova.pdf . Accessed April 29, 2016.
67. Bays HE, Tighe AP, Sadovsky R, Davidson MH. Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications. Expert Rev Cardiovasc Ther. 2008;6:391–409.
    https://doi.org/10.1586/14779072.6.3.391
68. Le Jossic-Corcos C, Gonthier C, Zaghini I, Logette E, Shechter I, Bournot P. Hepatic farnesyl diphosphate synthase expression is suppressed by polyunsaturated fatty acids. Biochem J. 2005;385:787–94.
    https://doi.org/10.1042/BJ20040933
69. Horton JD, Bashmakov Y, Shimomura I, Shimano H. Regulation of sterol regulatory element binding proteins in livers of fasted and refed mice. Proc. Natl Acad Sci USA. 1998;95:5987–5992.
    https://doi.org/10.1073/pnas.95.11.5987
70. Park Y, Harris WS. Omega-3 fatty acid supplementation accelerates chylomicron triglyceride clearance. J Lipid Res. 2003;44:455–63.
    https://doi.org/10.1194/jlr.M200282-JLR200
71. Harris WS, Bulchandani D. Why do omega-3 fatty acids lower serum triglycerides? Curr Opin Lipidol. 2006;17:387–93.
    https://doi.org/10.1097/01.mol.0000236363.63840.16
72. Khan S, Minihane AM, Talmud PJ, et al. Dietary long-chain n-3 PUFAs increase LPL gene expression in adipose tissue of subjects with an atherogenic lipoprotein phenotype. J Lipid Res. 2002;43:979–85.
    https://doi.org/10.1016/S0022-2275(20)30473-9
73. Reiffel JA, McDonald A. Antiarrhythmic effects of omega-3 fatty acids. Am J Cardiol. 2006;98:50i–60i.
    https://doi.org/10.1016/j.amjcard.2005.12.027
74. Robinson JG, Stone NJ. Antiatherosclerotic and antithrombotic effects of omega-3 fatty acids. Am J Cardiol. 2006;98:39i–49i.
    https://doi.org/10.1016/j.amjcard.2005.12.026
75. Mori TA, Beilin LJ. Omega-3 fatty acids and inflammation. Curr Atheroscler Rep. 2004;6:461–7.
    https://doi.org/10.1007/s11883-004-0087-5
76. Wang Q, Liang X, Wang L, et al. Effect of omega-3 fatty acids supplementation on endothelial function: a meta-analysis of randomized controlled trials. Atherosclerosis. 2012;221:536–43.
    https://doi.org/10.1016/j.atherosclerosis.2012.01.006
77. Vandongen R, Mori TA, Burke V, Beilin LJ, Morris J, Ritchie J. Effects on blood pressure of omega 3 fats in subjects at increased risk of cardiovascular disease. Hypertension. 1993;22:371–9.
    https://doi.org/10.1161/01.HYP.22.3.371
78. Wei MY, Jacobson TA. Effects of eicosapentaenoic acid versus docosahexaenoic acid on serum lipids: a systematic review and meta-analysis. Curr Atheroscler Rep. 2011;13:474–83.
    https://doi.org/10.1007/s11883-011-0210-3
79. Morton A, Furtado J, Amerine W, Kling D, Davidson M, Sacks F. The effect of omega-3 carboxylic acids on apolipoprotein CIII containing lipoproteins in moderate to severe hypertriglyceridemia. Circulation. 2014;130(Suppl 1):A16864.
80. Harris WS, Ginsberg HN, Arunakul N, et al. Safety and efficacy of Omacor in severe hypertriglyceridemia. J Cardiovasc Risk. 1997;4:385–91.
    https://doi.org/10.1097/00043798-199710000-00011
81. Pownall HJ, Brauchi D, Kilinc C, et al. Correlation of serum triglyceride and its reduction by omega-3 fatty acids with lipid transfer activity and the neutral lipid compositions of high-density and low-density lipoproteins. Atherosclerosis. 1999;143:285–97.
    https://doi.org/10.1016/S0021-9150(98)00301-3
82. Davidson MH, Stein EA, Bays HE, et al. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study. Clin Ther. 2007;29:1354–67.
    https://doi.org/10.1016/j.clinthera.2007.07.018
83. Bays HE, Ballantyne CM, Kastelein JJ, Isaacsohn JL, Braeckman RA, Soni PN. Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial). Am J Cardiol. 2011;108:682–90.
    https://doi.org/10.1016/j.amjcard.2011.04.015
84. Ballantyne CM, Bays HE, Kastelein JJ, et al. Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study). Am J Cardiol. 2012;110:984–92.
    https://doi.org/10.1016/j.amjcard.2012.05.031
85. Kastelein JJ, Maki KC, Susekov A, et al. Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial. J Clin Lipidol. 2014;8:94–106.
    https://doi.org/10.1016/j.jacl.2013.10.003
86. Maki KC, Orloff DG, Nicholls SJ, et al. A highly bioavailable omega-3 free fatty acid formulation improves the cardiovascular risk profile in high-risk, statin-treated patients with residual hypertriglyceridemia (the ESPRIT trial). Clin Ther. 2013;35:1400–11.
    https://doi.org/10.1016/j.clinthera.2013.07.420
87. Tsujita T, Okuda H. The synthesis of fatty acid ethyl ester by carboxylester lipase. Eur J Biochem. 1994;224:57–62.
    https://doi.org/10.1111/j.1432-1033.1994.tb19994.x
88. Beckermann B, Beneke M. Seitz I [Comparative bioavailability of eicosapentaenoic acid and docasahexaenoic acid from triglycerides, free fatty acids and ethyl esters in volunteers]. Arzneimittelforschung. 1990;40:700–4.
89. Davidson MH, Johnson J, Rooney MW, Kyle ML, Kling DF. A novel omega-3 free fatty acid formulation has dramatically improved bioavailability during a low-fat diet compared with omega-3-acid ethyl esters: the ECLIPSE (Epanova® compared to Lovaza® in a pharmaco*kinetic single-dose evaluation) study. J Clin Lipidol. 2012;6:573–84.
    https://doi.org/10.1016/j.jacl.2012.01.002
90. Maki KC, Keane WF, Bouhajib M, Pop R, Bobotas G. Pharmaco*kinetics of MAT9001, an omega-3 fatty acid medication, compared with eicosapentaenoic acid ethyl esters in hypertriglyceridemic subjects. FASEB. 2016;30(S1198):7.
91. Albert BB, Derraik JG, Cameron-Smith D, et al. Fish oil supplements in New Zealand are highly oxidised and do not meet label content of n-3 PUFA. Sci Rep. 2015;5:7928.
    https://doi.org/10.1038/srep07928

Functional Foods as Source of Bioactive Principles: Some Marked Examples

Adriana Campos, Elisa Brasili, Camile Cecconi Cechinel-Zanchett, Valdir Cechinel Filho

https://doi.org/10.1007/978-3-030-00545-0_4

Hypertriglyceridemia, an Underestimated Cardiovascular Risk Factor: An Epidemiological Study of the Rome Area

Roberto Volpe, On behalf of the Gruppo Progetto DATAMeg, Giulio Nati, Alberto Chiriatti, Massimo Sabatini, Fabio Valente

https://doi.org/10.1007/s40292-017-0222-3

Treating Hypertriglyceridemia-Induced Pancreatitis With Intravenous Insulin and Plasmapheresis

Lay She Ng, Si Yuan Khor, Wern Lynn Ng

https://doi.org/10.7759/cureus.30237

Dispelling myths about intravenous fish oil-based lipid emulsions

Michele ApSimon

https://doi.org/10.1097/mco.0000000000000445 ·

Very Severe Hypertriglyceridemia in a Large US County Health Care System: Associated Conditions and Management

Maria Isabel Esparza, Xilong Li, Beverley Adams-Huet, Chandna Vasandani, Amy Vora, Sandeep R Das, Abhimanyu Garg, Zahid Ahmad

https://doi.org/10.1210/js.2019-00129 · Full text

Hypertriglyceridemia and omega-3 fatty acids: Their often overlooked role in cardiovascular disease prevention

M. Arca, C. Borghi, R. Pontremoli, G.M. De Ferrari, F. Colivicchi, G. Desideri, P.L. Temporelli

https://doi.org/10.1016/j.numecd.2017.11.001 · Full text

Review of Cardiometabolic Effects of Prescription Omega-3 Fatty Acids

Megan F. Burke, Frances M. Burke, Daniel E. Soffer

https://doi.org/10.1007/s11883-017-0700-z ·

The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk

Pratik B Sandesara, Salim S Virani, Sergio Fazio, Michael D Shapiro

https://doi.org/10.1210/er.2018-00184 · Full text

The Possible Role of Nutraceuticals in the Prevention of Cardiovascular Disease

Angela Albarosa Rivellese, Paola Ciciola, Giuseppina Costabile, Claudia Vetrani, Marilena Vitale

https://doi.org/10.1007/s40292-019-00309-5

Therapeutic potential of omega-3 fatty acid-derived epoxyeicosanoids in cardiovascular and inflammatory diseases

Wolf-Hagen Schunck, Anne Konkel, Robert Fischer, Karsten-Henrich Weylandt

https://doi.org/10.1016/j.pharmthera.2017.10.016

About this publication